Improving care for patients with Graves' disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of person-centred care (PCC) on patients suffering from mental fatigue after experiencing Graves' disease, a common form of hyperthyroidism. It aims to engage patients as active partners in their care, promoting positive coping strategies and enhancing self-efficacy. The hypothesis is that PCC will lead to improvements in mental fatigue, reduced sick leave, and lower recurrence rates of Graves' disease. The study will involve patients aged 18-65 who are experiencing their first episode of Graves' disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-65 years
* First time Graves' diseases with elevated FT4 and/or FT3 and positive TSH receptor antibody (TRAb)

Exclusion Criteria:

* Patients that cannot attend to the protocol
* Patients with moderate-severe/ severe Graves' eye disease

Where it's running

• Agneta Lindo
  Gothenburg, Sweden Recruiting

Study contacts

• Principal investigator: Helena Filipsson Nyström — Sahlgrenska Universitet sjukhus
• Study coordinator: Agneta Lindo
• Email: agneta.lindo@vgregion.se
• Phone: +46766185481

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Efgartigimod for Graves' Disease in adults

  We are testing if efgartigimod given under the skin can help adults with Graves' disease by improving thyroid function and whether it is safe and tolerable.

  Recruiting at 35 sites Phase 3 argenx · Carlsbad, California and 34 other locations · NCT07570316

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Early risk stratification of thyroid eye disease in newly diagnosed Graves' disease

  This study tests whether early eye-related signs, blood and tear biomarkers, or eye surface features can predict who with Graves’ disease will develop thyroid eye disease within a year.

  Recruiting University of Copenhagen · Herlev · NCT07812194

• Felzartamab for Graves’ Disease: See if it helps control thyroids and reduce need for ATDs

  This study tests felzartamab vs placebo in adults with Graves’ disease to see if it can normalize thyroid hormones and let people stop anti-thyroid drugs.

  Recruiting at 14 sites Phase 2 Biogen · Glendale, Arizona and 13 other locations · NCT07722546

• AI-based MRI and ultrasound for thyroid-related eye disease

  This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Huangpu District · NCT07716397

• YB-101 for Graves' Disease: safety, dosing, and how it works

  This study tests YB-101 versus placebo in adults with Graves' disease to see if it is safe, tolerated, and whether it can help thyroid symptoms over about 40 weeks.

  Recruiting at 25 sites Phase 2 Yarrow Bioscience, Inc. · Gilbert, Arizona and 31 other locations · NCT07682896

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.